ARTICLES BY LOUIS

• Physical Security For The Pharma Supply Chain

  8/20/2015

  Charles “Chuck” Forsaith quietly enters his Purdue Pharma office as the light of day lands on Stamford, Connecticut. For a little over an hour he pours over intelligence briefings on illicit drug activity around the globe. Sound like the start of a Tom Clancy novel? Rather, it’s the reality of a security professional charged with assessing supply-chain risk for pharmaceuticals.    

• Breaking Down Silos In The Field of Pharma

  8/14/2015

  Silos are as prevalent in the Pharma-related industries as anywhere else. But nearly 30 years after the term “functional silo syndrome” was coined, our medicine to get rid of silos may be equal parts as bad as the malady. The most recently announced attempt to reorganize out of silos — and into a more cross-functional approach — is at Catalent Pharma Solutions. 

• From J&J To Cognitive Psychology: Lifecycle Insights For Pharma

  8/6/2015

  William King was a career J&J executive who decided he had to leave the company. Ironically, it was so he could devote himself to solving a growing challenge there. “We had these important ‘lifecycle insights’ that we couldn’t take action on, despite having all these data points coming in,” says the CEO of Zephyr Healthcare. 

• Breaking News: Select Your CMO With Three (Well-Known) Attributes

  8/3/2015

  Here’s your news bulletin: Another experienced source goes on record sharing three basics to selecting the best CMO: credibility, work ethic, and relationships. “I gained experience and understanding of outsourcing from running our own CRO,” says Chris K. Achar, CEO of Genzum Life Sciences.

• BioPharma Fears CMO Capacity Crunch

  7/24/2015

  Fear is discernable in the voices of executives at BioPharma companies when considering a capacity crunch at CMOs. There’s also a rising resignation. Getting on CMO production schedules and securing commitments is a here-and-now challenge.

• Can This Outsourcing Model Save Health Care?

  7/15/2015

  A company has been formed to push aside the intermediaries standing between new drugs and the patients that need them. In the process, says Cynthia LaConte, CEO of Dohmen Life Science Services, this model of “intelligent outsourcing” will start to improve health care efficiencies and lower costs.

• An All-Outsourcing Model For Orphan Drugs

  6/15/2015

  Nils U. Olsson, VP of Chemistry, Manufacturing and Controls at Retrophin Inc., says his company’s business model targeting new drugs for orphan diseases allows for a perfect application of an all-outsourcing strategy. 

• Silicon Valley Targets CRO Industry For Market Disruption

  5/22/2015

  The techies in Silicon Valley are at it again. This time it’s the contract research industry targeted for disruption. “We now look at the Science Exchange as the best way of finding new outsourcing opportunities,” says James Lillie, VP In Vitro Biology, Genzyme.  Will other research sponsors and CROs lose out on new opportunities if they don’t, too?

• CROs/CMOs Powering Vaccine R&D At Biotechs

  5/18/2015

  There’s a vitality in in the biotech space, supported in large part by CROs/CMOs, for vaccine innovation. Where does that intersect with the troubled commercial-scale vaccine market? And if commercialization leads to a low-margin future, even if biotechs can fill the innovation gap, why would they want to?  

• Sanofi Pasteur: Vaccine Ecosystem In Danger

  5/12/2015

  The intent was to investigate outsourcing in the innovative vaccine industry. However, it became obvious we’d first need to decipher a Kafkaesque world of organizations and markets. “There are strong warning signs out there,” says Michael Watson, VP of Global Immunization Policy, Sanofi Pasteur.